Skip to main
SNTI
SNTI logo

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc., a clinical-stage biotechnology firm, is advancing its innovative gene circuit platform technologies through multiple product candidates, notably SENTI-202 and SENTI-301A, which target oncology indications with promising preclinical outcomes. The company's focus on allogeneic CAR-NK cells suggests a potentially safer profile compared to traditional CAR-T therapies, which is supported by statistically significant enhancements in anti-tumor activity and patient survival in preclinical models. Additionally, the designation of Orphan Drug Designation (ODD) for SENTI-202 indicates favorable regulatory support, potentially enabling Senti to secure strategic partnerships and investor interest while establishing a robust clinical supply ahead of critical data releases scheduled for 4Q25.

Bears say

Senti Biosciences Inc. faces significant challenges that contribute to a negative outlook on its stock. Key concerns include the expectation of a decline in complete response (cCR) rates from the initial 57% due to the aggressive nature of acute myeloid leukemia (AML), which raises doubts about clinical efficacy and potential revisions to financial projections. Furthermore, the company has notable risks related to safety signal emergence, competition, regulatory approvals, cash runway beyond 2025, and the need for substantial additional financing, all of which may hinder its growth and performance compared to competitors within the allogeneic cell therapy market.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.